2024
DOI: 10.1159/000538347
|View full text |Cite
|
Sign up to set email alerts
|

Cardiorenal benefits of finerenone in different races and kidney function in patients with chronic kidney disease

Pingjiang Li,
Yuying Cui,
Xiaoming Xu
et al.

Abstract: Background: Mineralocorticoid receptor plays an important pathophysiological role in cardiorenal diseases by causing inflammation and fibrosis. Mineralocorticoid receptor antagonists (MRAs) are well known in treating cardiovascular disease and diverse nephropathies. However, the first-generation MRA (spironolactone) and the second-generation MRA (eplerenone) remain underutilized because of the risk of inducing severe adverse events. As a selective non-steroidal MRA, finerenone is safer and more effective and i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 42 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?